ArticleFrontiers in oncology2026
Pituitary T-lymphoblastic lymphoma combined with pituitary adenoma: a rare case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive malignancy that originates from immature precursor T lymphocytes and is characterized by rapid progression. The typical clinical manifestations of T-LBL include superior vena cava syndrome and respiratory compression symptoms such as cough and dyspnea caused by large anterior mediastinal masses. Primary pituitary T-LBL is exceptionally rare, with only seven cases reported worldwide (including the case described in this study). Case presentation: This article presents the case of an elderly female patient who presented with headaches and progressive visual deterioration. Brain MRI revealed a sellar/suprasellar mass, while whole-body PET/CT imaging revealed a tumor confined to the central nervous system. Laboratory tests for blood parameters and pituitary hormone levels were normal. Following neuroendoscopic tumor resection, pathological examination and immunohistochemical analysis confirmed a diagnosis of pituitary T-LBL coexisting with pituitary adenoma. The patient's headaches and visual impairment were resolved postoperatively. Subsequent chemotherapy with high-dose methotrexate (HD-MTX), temozolomide, and liposomal doxorubicin effectively controlled the disease. Conclusions: This case highlights the rarity of concurrent sellar lymphoma and pituitary adenoma and summarizes previously reported cases of primary pituitary T-LBL to provide clinical diagnostic and therapeutic insights into this rare disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.